See the DrugPatentWatch profile for Advair
When does the Advair (fluticasone/salmeterol) patent expire?
“Advair” is used to describe multiple branded products (most commonly Advair Diskus and Advair HFA), which rely on different underlying patents. Patent expiration dates therefore vary by product strength and by which specific patent family you mean (for example, the original drug substance/formulation patent versus later “method of use” or formulation patents).
How long is exclusivity in the U.S. if patents are still active?
In the U.S., even after a patent’s stated expiration, FDA marketing can still be blocked by other listed patents tied to the drug in the Orange Book, or by additional periods of regulatory exclusivity (these depend on the specific product and exclusivity category). That means “patent expiration” and “when a generic can launch” are often different dates.
What do generic challengers look for with Advair patents?
Generic and inhalation-combination challengers typically review:
- Which patents are listed for the specific Advair product/strength in the FDA Orange Book
- Whether the challenger can file a Paragraph IV certification against those patents
- Whether other remaining patents would still prevent approval/launch
Because multiple patents can remain in force, multiple court rulings and settlement terms can affect the practical launch timeline.
Where can I find the specific Advair patent expiry dates?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, and it’s one of the most direct ways to locate the specific patent numbers and the expiration/possible blocking dates that apply to each Advair product. You can use it to narrow down the exact Advair product (Diskus vs HFA) and then check the related patent timeline here: https://www.drugpatentwatch.com/ .
Which Advair product should you check (Diskus vs HFA)?
If your goal is the “earliest date” a generic could launch, you need the exact product name and strength because:
- Each marketed product has its own Orange Book listing
- Different strengths can have different patent associations
- Later-life patents (formulation/device-related) may attach to one branded product variant but not another
Can biosimilars or authorized generics change the timeline?
Advair is a small-molecule combination inhaler, so “biosimilar” doesn’t apply the way it does for biologics. The practical competitive timeline usually turns on whether ANDA generics can get approved and when they’re allowed to launch, which can hinge on remaining patents and any exclusivity listed in the Orange Book.
If you tell me the exact Advair version, I can pinpoint the expiry
Reply with which one you mean—Advair Diskus or Advair HFA (and, if you know it, the strength). With that, the patent expiration question can be answered with the relevant specific patents and dates rather than a general “Advair” timeframe.
Sources:
- 1 DrugPatentWatch.com